The historical rank and industry rank for The IBN SINA Pharmaceutical Industry's Return-on-Tangible-Equity or its related term are showing as below:
DHA:IBNSINA's Return-on-Tangible-Equity is not ranked *
in the Drug Manufacturers industry.
Industry Median: 7.9 * Ranked among companies with meaningful Return-on-Tangible-Equity only.
The IBN SINA Pharmaceutical Industry (DHA:IBNSINA) Return-on-Tangible-Equity Explanation
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
The IBN SINA Pharmaceutical Industry Return-on-Tangible-Equity Related Terms
The IBN SINA Pharmaceutical Industry Return-on-Tangible-Equity Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
The IBN SINA Pharmaceutical Industry Return-on-Tangible-Equity Chart
The IBN SINA Pharmaceutical Industry Annual Data
Trend
Return-on-Tangible-Equity
The IBN SINA Pharmaceutical Industry Semi-Annual Data
Return-on-Tangible-Equity
DHA:IBNSINA vs IMNPQ: Return-on-Tangible-Equity Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, The IBN SINA Pharmaceutical Industry's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
The IBN SINA Pharmaceutical Industry Return-on-Tangible-Equity vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, The IBN SINA Pharmaceutical Industry's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where The IBN SINA Pharmaceutical Industry's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is one times the annual (. 20) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 0.00% mean?
The IBN SINA Pharmaceutical Industry (DHA:IBNSINA) has a Return-on-Tangible-Equity of 0.00% as of . 20. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on The IBN SINA Pharmaceutical Industry and its competitors. According to the industry distribution chart, The IBN SINA Pharmaceutical Industry ranks #999999 out of 897 companies in the Drug Manufacturers industry.
Is The IBN SINA Pharmaceutical Industry's Return-on-Tangible-Equity too high?
The IBN SINA Pharmaceutical Industry's current Return-on-Tangible-Equity is 0.00%. Based on the distribution chart, The IBN SINA Pharmaceutical Industry ranks #999999 out of 897 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, The IBN SINA Pharmaceutical Industry has a GF Score™ of 20/100, reflecting its overall financial health beyond just this single metric.
How does The IBN SINA Pharmaceutical Industry's Return-on-Tangible-Equity compare to IMNPQ?
According to the Drug Manufacturers industry distribution chart, The IBN SINA Pharmaceutical Industry ranks #999999 out of 897 companies for Return-on-Tangible-Equity. This places The IBN SINA Pharmaceutical Industry in the lower half of its industry. The industry median Return-on-Tangible-Equity is 7.90. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Drug Manufacturers company?
The median Return-on-Tangible-Equity among Drug Manufacturers companies is 7.90, based on 897 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on The IBN SINA Pharmaceutical Industry and its competitors. For the Drug Manufacturers industry, the median Return-on-Tangible-Equity is 7.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. The IBN SINA Pharmaceutical Industry's current Return-on-Tangible-Equity is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is The IBN SINA Pharmaceutical Industry stock overvalued right now?
The IBN SINA Pharmaceutical Industry (DHA:IBNSINA) has a current Return-on-Tangible-Equity of 0.00%. The current Return-on-Tangible-Equity is 0.00%. The IBN SINA Pharmaceutical Industry's overall GF Score™ is 20/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For The IBN SINA Pharmaceutical Industry (DHA:IBNSINA), the current Return-on-Tangible-Equity is 0.00% as of . 20. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
The IBN SINA Pharmaceutical Industry Business Description
The IBN SINA Pharmaceutical Industry PLC is engaged in the production and marketing of pharmaceutical drugs and natural medicines in both the local and international market.
20GF Score
Get the complete analysis for DHA:IBNSINA
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DHA:IBNSINA has been successfully added to your 